Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

R&D In Brief

This article was originally published in The Tan Sheet

Executive Summary

Acetaminophen and ovarian cancer: A meta-analysis published in the July British Journal of Clinical Pharmacology "supports a protective association between acetaminophen use and ovarian cancer and provides evidence for a dose effect." However, the potential association between the drug and the disease "deserves further verification, since proof of chemoprevention would represent a major public health advance," Stefanos Bonovas, University of Athens, Greece, et al., state. Researchers analyzed eight studies (four case-control and four cohort studies) published between 1998 and 2004 and concluded that an inverse association exists between acetaminophen use and ovarian cancer risk. The association "was marginally significant assuming a random-effects model...but not statistically significant assuming a fixed-effects model"...
Advertisement

Related Content

Vectomega distribution deal
Vectomega distribution deal
Vectomega distribution deal

Topics

Advertisement
UsernamePublicRestriction

Register

PS099570

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel